ArticleClinical and translational medicine2024

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.

Antoine Desilets et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.